AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AstraZeneca to invest $50B in US to boost drug manufacturing and R&D
AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant's largest-ever investment in a single market. The UK-headquartered biopharmaceutical company said the investment will expand its domestic manufacturing and research footprint as it works toward a long-term revenue target of $80 billion annually, with half of that total expected to come from the US market.
5 Things to Know Before the Stock Market Opens
Stock futures are little changed as investors watch for more earnings and trade developments; AstraZeneca (AZN) said it plans to invest $50 billion in U.S. production facilities; Opendoor Technologies (OPEN) shares are on the rise as retail investors continue to pile into the meme stock; and OpenAI and Softbank are reportedly paring back near-term plans for their $500 billion Stargate project. Here's what investors need to know today.
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
AstraZeneca (AZN) said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about President Donald Trump's tariffs loom over the industry.
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it's already announced before.
AstraZeneca announces $50bn US investment in manufacturing and R&D
AstraZeneca PLC (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, marking its largest-ever commitment to a single country and signalling a major boost for domestic drug manufacturing and research. The centrepiece of the investment is a proposed multi-billion-dollar drug manufacturing facility in Virginia, which would be the company's largest single site worldwide.
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca has become the latest pharma firm to announce a multi-billion investment in the U.S. The Anglo-Swedish biotech firm has committed to spend $50 billion by 2030.
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in organs.
